The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unve...
Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout
The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.
Author: Fierce Pharma
Read Original Article